Orbimed and Alta Partners figure prominently among 2014's 20 largest US-based VC-backed healthcare exits.

Venture-backed life science IPOs far exceeded tech IPOs in terms of quantity in 2014. Besides being plentiful in number, VC-backed healthcare exits also racked up some large valuations with the top 20 life science exits of 2014 being valued at $13.9B. The top two healthcare investors per Investor Mosaic (OrbiMed Advisors and Alta Partners) saw multiple entrants in the top 20 exits of 2014.

OrbiMed’s largest exit came with Seragon Pharmaceuticals, who was acquired for $1.7B (including earn outs) by Genentech in July. Alta Partners’ biggest healthcare exit of the year was in Kite Pharma’s June IPO which valued the company at $632M. There are a mix of pharma, biotech and medical device deals in the list below.

Luke Evnin, co-founder of MPM Capital argued in a guest post earlier this year that biotech venture capital is where it’s at. Given the exit and IPO health of the life sciences sector in 2014, 2015 should be a banner year.


The full list of the 20 largest VC-backed healthcare exits of 2014 below. Juno’s flagship IPO ended a banner year for big healthcare exits.

20 Largest US-Based VC-Backed Healthcare Exits of 2014
Company Exit Type Valuation ($M) Select Investors
Juno Therapeutics IPO 1870 ARCH Venture Partners, Bezos Expeditions, Venrock, Alaska Permanent Fund
Alios BioPharma Acquisition (Johnson & Johnson) 1750 Novartis Venture Funds, SR One, Novo Ventures
Seragon Pharmaceuticals Acquisition (Genentech) 1700 OrbiMed Advisors, Aisling Capita, venBIO
Labrys Biologics Acquisition (Teva Pharmaceuticals) 825 InterWest Partners, Canaan Partners, Sofinnova Ventures, venBIO
Kite Pharma IPO 632.4 Alta Partners, Pontifax, TPG Capital
Ultragenyx Pharmaceutical IPO 610.3 TPG Biotech, T. Rowe Price, Healthcap Venture Capital, Pappas Ventures, Fidelity Biosciences
Ulthera Acquisition (Merz Pharma Group) 600 New Enterprise Associates, 3i Group, Apposite Capital
iPierian Acquisition (Bristol-Myers Squibb) 550 Kleiner Perkins Caufield & Byers, MPM Capital, Google Ventures
Topera Medical Acquisition (Abbott Laboratories) 550 New Enterprise Associates
Civitas Therapeutics Acquisition (Acorda Therapeutics) 525 Longitude Capital, OrbiMed Advisors, Canaan Partners
PreCision Dermatology Acquisition (Valeant Pharma) 500 Boston Millennia Partners, Longitude Capital, Frazier Healthcare, Quaker BioVentures
Versartis IPO 488.6 Index Ventures, New Leaf Venture Partners, Advent Venture Partners
Pneumrx Acquisition (BTG) 475 Silicon Valley Bank, Alta Partners, Adams Street Partners
CardioMems Acquisition (St. Jude Medical) 455 Arboretum Ventures, Boston Millennia Partners, Johnson & Johnson
SAGE Therapeutics IPO 449.3 ARCH Venture Partners, OrbiMed Advisors, Third Rock Ventures
Coherus BioSciences IPO 432.7 Venrock, Fidelity Biosciences, Lilly Ventures
Nevro IPO 423.8 New Enterprise Associates, MPM Capital, Three Arch Partners
Small Bone Innovations Acquisition (Stryker) 375 3i Group, NGN Capital, Axiom Venture Partners
InnoPharma Acquisition (Pfizer) 360 Comerica Bank, Thomas McNerney & Partners, NXT Capital
Avalanche Biotechnologies IPO 353.2 Venrock, Deerfield Management, Redmile Group

To track life science financing and exits, login to CB Insights or create a free account below.


  • Dana Callow

    Good to see these results. By the way, Boston Millennia Partners originated the Precision Dermatology investment and was the lead first round investor in its spin out from Collegium Pharmaceuticals in addition to our lead investment in CardioMems, so 2 in the top 20. We will make sure the data gets forwarded in the future.

    Best Regards, Dana Callow, Managing Partner, Boston Millennia Partners